FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11

<p>Expanded indication for ZORYVE provides new, steroid-free topical for children 6 to 11 with plaque psoriasis, including intertriginous psoriasis WESTLAKE VILLAGE, Calif., Oct. 06, 2023 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the U.S. Food and Drug Administration (FDA) has […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/fda-approves-arcutis-zoryve-roflumilast-cream-0-3-for-treatment-of-psoriasis-in-children-ages-6-to-11/">FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>